▲ October 26-27, Chengdu India’s clinical trial industry development conference, click free registration
Note: This article does not constitute any investment opinions and suggestions, and is based on the official/company announcement; this article is only introduced by medical and health -related drugs. Non -therapy recommendations (if they are involved), do not represent the platform position.Any article reprint needs to be authorized.
On October 1, 2024, Kailera therapeutics officially announced its establishment.CEO is Ron Ronaud, who has led CNS leading company Cerevel Therapeutics and was acquired by ABBVIE (Abervi) $ 8.7 billion; then Bain Capital was added as a senior consultant.
Hengrui Pharmaceutical’s HRS9531 will be renamed Kai-9531 overseas; other categories.In addition, Gilead Sciences’s former CEO John Milligan, PH.D. is the chairman of the board of directors of the new company Kailera.Guoabong Wealth Management
Weight loss drug strategy: Establish product lines to meet the needs of more patients
Data Monitoring of Yao Rongyun shows: On May 16, 2024, Hengrui Pharmaceutical will be autonomous
The GLP-1 product portfolio of intellectual property rights can be called Hercules CM Newco, Inc.
Hercules will obtain exclusive rights to develop, produce and commercialize the GLP-1 product portfolio in global development, production and commercial GLP-1 product portfolio except Greater China.Kolkata Investment
As part of the foreign license transaction consideration, Hengrui obtained 19.9%of the Hercules Company of the United States and will obtain the GLP-1 product portfolio license from Hercules, the United States.The consideration of this License Out transaction: $ 100 million down payment, and a recent milestone after the transfer of 10 million US dollars; the milestone of the development and supervision of 200 million US dollars, the cumulative milestone of not more than 5.725 billion US dollars; the total total amount of about $ 6 billion.As well as sales commission with a low single -digit proportion of double -digit sales of actual annual net sales.
Hercules CM Newco, Inc. Company, established in Tellawa, USA in May 2024.Shareholders include: Bain Capital Life Sciences, RTW Capital, ATLAS, LYRA Capital, etcJaipur Stock. jointly invested 400 million US dollars.
Joint Management Commission: Hengrui and the United States Hercules set up a joint management committee to coordinate the development and commercialization of products globally with a coordinated license product. The two parties have all assigned three representatives to the joint management committee.
Hercules company pipeline, GLP-1 product portfolio candidate candidate, including:
(1) HRS-7535, small molecular GLP-1 receptor agonist;
(2) HRS9531, polypeptide GLP-1/GIP dual receptor agonist injection and oral products;
(3) HRS-4729, the next generation of intestinal insulin products.(3 new drugs, GLP-1/GIP/Glucagon Receptor Tri-Agonist)
HRS-7535 tablets are a new type of oral small-molecule high-blood glucose peptide-1 receptor (GLP-1r) agonist, which can promote insulin secretion and reduce pancreatic hypotonin by activating people’s GLP-1R.point
The secretion and inhibit stomach emptiness can also be used to treat the center of fullness and suppress appetite by affecting the center, and directly reduce energy intake for treatment. 2
Diabetes (T2DM) and weight loss.Globe GLP-1R agonist is not yet available globally.It is expected to be an important molecule in the pipeline.
Hrs9531
Injecting solution is a targeted gastric peptide body (GIPR) and pancreatic hypotonal peptide-1
The double excitement agent of the receptor (GLP-1R) can coordinate to promote insulin secretion, inhibit energy intake, and improve insulin sensitivity, and effectively accelerate lipid metabolism and reduce GLP-1 by excitement GIPR.
The cause of adverse gastrointestinal tract is used to treat type 2 diabetes (T2DM) and weight loss.Tirzeptide in Lili Lilly in the same target drug was 5 in 2022 5
Month is approved in the United States (product name: Mounjaro) for treatment of type 2 diabetes.In addition, Tirzeptide
Two phase III clinical studies for obese patients have been successful and have been qualified for FDA fast channel.
HRS9531 is a new oral GIPR and GLP-1R dual agonist with HRS9531 with HRS9531 as the main active ingredients, which can increase the absorption of HRS9531 in the gastrointestinal tract in the body for treatment of T2DM and weight loss.There are no oral products worldwide to go public around the world.HRS9531 is expected to be the most valuation molecules in the pipeline.
Hrs-4729
The injection is the self -developed next -generation bowel -promoting insulin products. By activating multi -target, it can protect the islet while improving insulin secretion and controlling blood sugar. It is expected to achieve a better weight loss effect and the treatment of metabolic dysfunction related diseases.It is currently in the stage of clinical development.There are no similar products globally.
Hengrui Pharmaceutical: At present, the company has invested nearly 40 billion yuan in R & D, and has been listed in 16 innovative drugs, 4 new drugs in China, and more than 90 independent innovative products are being developed in clinical. Nearly 300 clinical trials are in China in ChinaExternal development.In addition to deeply cultivating the traditional advantages of the tumor field, the company also actively expands key slow diseases such as autoimmune diseases and metabolic diseases.
In the field of metabolic diseases, after many years of precipitation and layout, the company has more than 10 products under research, of which two types of 1 type of hypoglycemic innovative drug Hengge Line, Rigerine and hypoglycemic new drugs Hengge Line Jinghe Jinghe Jingge Line JinghejingThe two -metal dual -胍 片 (i) (i) (ii) was approved in China, and the two diabetic compound preparations were approved for listing.In addition to the development and development of the hot direction of the GLP-1 circuit in the field of hypoglycemic/weight loss, the company has also made a layout in the field of insulin, insulin/GLP-1 compound preparations.
NMPA/CDE;
FDA/EMA/PMDA;
Related companies publicly disclosed; Kailera;
Phase 2 data progress,
2023 Hengrui Pharmaceutical R & D Day;Guoabong Stock
This article is only used to provide scientific information to medical professionals, does not represent the platform position.
【About Medicine Ring Circle】
PRHUB aims to help biomedical technology enterprises carry out brand promotion and business expansion services, and formulate systematic solutions for the real needs of customers.The way of understanding is known by the public, and at the same time, it covers the purpose of cooperation on the basis of traffic channels 1 million+vertical users, and help partners to complete closed -loop marketing services from the start of the brand to business.We have completed dozens of offline biomedical R & D conferences, covering new small molecular drugs, new drugs, improved new drugs, BD cross -border transactions and other fields, serving more than 100 listings/unicornBeast/Biotechnology/Pharmaceutical Company.
Lucknow Investment